Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Lichen planus
Clinical narrative: lichen planus; Shingles in the same body region four times with normal immune system otherwise; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 60-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 20Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 60 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Glaucoma" (unspecified if ongoing); "known allergies: Sulfa" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Covid-19" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Doxycycline, reaction(s): "Known allergies: Doxycycline"; Avelox, reaction(s): "Known allergies: Avelox". Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: Unknown., Location of injection: Arm Left, Vaccine Administration Time: 12:00 AM, Route of Administration: Intramuscular), administration date: 29Jan2021, when the patient was 59-year-old, for COVID-19 immunization, reaction(s): "Shingles in the same body region four times with normal immune system otherwise: Sep2021"; BNT162b2 (Dose Number: 1, Batch/Lot No: Unknown., Location of injection: Arm Left, Vaccine Administration Time: 12:00 AM, Route of Administration: Intramuscular), administration date: 01Jan2021, when the patient was 59-year-old, for COVID-19 immunization; shingrix (completed), administration date: 23Oct2020, when the patient was 59-year-old, for immunisation. The following information was reported: HERPES ZOSTER (medically significant) with onset Dec2021, outcome "not recovered", described as "Shingles in the same body region four times with normal immune system otherwise"; LICHEN PLANUS (medically significant) with onset May2022, outcome "not recovered". The events "shingles in the same body region four times with normal immune system otherwise" and "lichen planus" required physician office visit. Therapeutic measures were taken as a result of herpes zoster, lichen planus. Clinical course: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and did not receive other medications within 2 weeks of vaccination. Patient had Shingles on Sep2021, Dec2021, May2022, and Dec2022. Patient received treatment of Valtrex, steroid injections, steroid cream. Patient had covid-19 prior vaccination and patient had tested for covid-19 post vaccination.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information available and product safety profile, the reported events Hepes zoster and Lichen planus are more likely due to intercurrent medical condition and unrelated to BNT162b2.  The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202300078579 Same patient/vaccine, different dose and event;US-PFIZER INC-202300078593 Same patient/vaccine, different dose and event;